uniQure announces closing of commercialization and license agreement with CSL Behring
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
uniQure BV (QURE) Risk/Reward 'Heavily Skewed To The Upside' - Raymond James
May 6, 2021 9:44 AM EDTRaymond James analyst Danielle Brill reiterated a Strong Buy rating and $75.00 price target on uniQure BV (NASDAQ: QURE) after announcing the licensing agreement with CSL Behring for its HemB gene therapy (etranacogene dezaparvovec (EtranaDez)) has closed.
"In our view, the hemophilia-B gene... More
uniQure (QURE) Removes 'Overhang' With CSL Deal Closure - Stfel
May 6, 2021 8:31 AM EDTStifel analyst Paul Matteis said the closing of the CSL deal removes an overhang from uniQure (NASDAQ: QURE).
The analyst commented, "We are reiterating our Buy Rating on QURE after the closing of the CSL deal for AMT-061, QURE's HemeB GTx where the... More
